AN OPEN LABEL PHASE Ia/b DOSE ESCALATION FOLLOWED BY DOSE EXPANSION SAFETY AND TOLERABILITY TRIAL OF CAP 100, A HUMANIZED C C CHEMOKINE RECEPTOR 7 ANTIBODY, ADMINISTERED AS MONOTHERAPY IN SUBJECTS WITH R/R CHRONIC LYMPHOCYTIC LEUKEMIA

Administered By

Awarded By

Contributors

Start/End

  • August 9, 2021 - September 5, 2026